

Supplementary Table 1. Characteristics and safety of blood products used.

	Before MTP		After MTP	
	GROUP 1 2005-2006 N = 96	GROUP 2A 2007-2009 N = 116	GROUP 2B 2010-2012 N = 92	
Fresh frozen plasma				
<i>FFP total single-donor units</i>	551	654	491	
<i>Riboflavin/UVA inactivated, n (%)</i>	(100)	(100)	(100)	
Platelets				
<i>Total PLT units</i>	158	176	125	
<i>Pooled units /apheresis, n (%)</i>	0 / 36 (100)	1 (2) / 52 (98)	30 (59) / 21 (41)	
<i>ABO compatibility, n (%)</i>	105 (67)	110 (63)	73 (59)	
<i>Rh compatibility, n (%)</i>	123 (78)	153 (87)	81 (65)	
Red Blood cells				
<i>Total RBC</i>	1340	1564	1111	
<i>Non cross-matched, n (%)</i>	40 (3)	250 (16)	112 (10)	
Transfusion-related adverse events				
<i>Non-haemolytic reactions</i>	4 (0.2)	2 (0.1)	3 (0.2)	
<i>Suspected TRALI/TACO*</i>	0	2 (0.2)*	0	

RBC: Red blood cells; FFP: Fresh frozen plasma; PLT: Platelets; TRALI: Transfusion-related acute lung injury; TACO: Transfusion-associated circulatory overload.

* All cases were mild pulmonary oedema after the transfusion, TRALI was not demonstrated based on anti-HLA antibody testing.